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Abstract 
Objective. Emerging evidence suggests that physical activity (PA) enhances cognition and may be a 
protective factor for attention-deficit/ hyperactivity disorder (ADHD). Yet, the impact of PA on ADHD 
symptoms has only been investigated in a few undersized, non-randomised and retrospective studies. 
We examined the effect of PA during late adolescence on ADHD symptoms in early adulthood while 
controlling for unmeasured genetic and shared environmental confounding. Methods. The effect of 
PA at age 16-17 (baseline) on ADHD symptoms at age 19-20 (follow-up) was examined using a 
within-monozygotic twins fixed-effects model in 232 monozygotic twin pairs born in Sweden between 
May 1985 and December 1986. Parents rated their children’s DSM ADHD symptoms at baseline and 
follow-up. Participants’ weekly energy expenditure (in metabolic equivalent task minutes/ week) was 
based on self-reports at baseline of PA frequency, intensity and duration. Results. Greater weekly 
energy expenditure in adolescence was significantly associated with reduced ADHD symptom levels 
in early adulthood, even when controlling for unmeasured confounding (all genetic and shared 
environmental factors shared within MZ twin pairs) and ADHD symptoms and BMI at baseline, 𝛽 =  -
0.21, p=0.013 (95% CI= -0.38 – -0.05). Similar results were observed for the two ADHD sub-
components; hyperactivity/ impulsivity,  𝛽 =  -0.21, p=0.022 (95% CI= -0.39 –  -0.03), and inattention, 𝛽 =  -0.19, p=0.049 (95% CI= -0.36 – -0.0005). Conclusion. In line with a causal hypothesis, PA was 
inversely associated with ADHD symptoms, even after adjusting for unmeasured confounding. These 
findings suggest that PA in adolescence might decrease ADHD symptoms in early adulthood. 
However, given the size of the effect, the clinical value of this intervention needs to be explored 
further.  
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Introduction 
Attention-deficit/ hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder 
characterised by developmentally inappropriate and impairing levels of hyperactivity, impulsivity, and/ 
or inattention1. Both the symptoms and functional impairments associated with ADHD persist from 
childhood into adolescence and adulthood in around 65% of cases2. Across the lifespan, ADHD is 
associated with a significant risk of lower academic and occupational achievement3, interpersonal 
problems, mental illness, and delinquency4. Multimodal treatment plans including psychostimulant 
medication, non-psychostimulant medication and psychological interventions, tailored to the specific 
needs of the patient, are recommended for the treatment of ADHD5. Due to their persistence, there is 
a continued need for treatment and management of ADHD symptoms and impairments from 
childhood through adolescence and into adulthood. 
 
A robust evidence base stemming from randomised control trials attests to the efficacy of 
psychostimulant and non-psychostimulant medication in reducing the symptoms of ADHD6. Yet, 
treatment with medication has its limitations. Some individuals may not respond to medication and 
complete normalisation of symptoms is rare7. Medication may be less effective for treating associated 
impairments of ADHD, such as poor social skills8 and executive function (EF) deficits9; and its long-
term effectiveness for control of ADHD symptoms and impairments is yet to be established10. Adverse 
side effects on sleep, appetite, and growth are also possible11. Furthermore, some patients, parents 
and clinicians have reservations about medication use12 and the majority of individuals who are 
prescribed medication stop taking it within the first year13.  These potential problems are 
acknowledged by the National Institute for Health and Care Excellence (NICE) clinical guidelines 
which recommend that non-medical interventions should be considered as possible first line treatment 
where ADHD is associated with moderate levels of impairment5. 
 
A variety of non-pharmacological interventions, such as psychological (cognitive training, 
neurofeedback, and behavioural training) and dietary (restricted elimination diets, artificial food colour 
exclusions, and free fatty acid supplementation) interventions, are also available. A recent meta-
analysis found blinded evidence that behavioural interventions used to treat children and adolescents 
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with ADHD had beneficial effects on important aspects of child and parent functioning, namely 
decreasing comorbid childhood conduct problems and increasing positive parenting14. 
Yet, the evidence for the efficacy of non-pharmacological treatment interventions on reducing ADHD 
symptoms is far from clear and limited by the unblind status of researchers and raters of behaviour as 
another recent meta-analysis by the same group concluded15. Blinded evidence for small but 
significant reductions in ADHD symptoms was found only for free fatty acid supplementation and 
artificial food colour exclusion15. 
 
Identifying new non-pharmacological treatments on the basis of our growing understanding of the 
pathophysiology as well as risk and protective factors of ADHD would, therefore, be a significant 
advance in the management of ADHD. Animal research as well as studies of typically developing 
children, adolescents and adults suggest physical activity (PA) and exercise as a putative treatment 
target, potentially diminishing an individual’s level of ADHD symptoms and associated impairments16. 
Here, PA is defined as any bodily movement, produced by skeletal muscles, that requires energy 
expenditure, while exercise is a subcategory of PA that is planned, structured, repetitive, and 
purposeful. Yet, more and better-quality evidence is needed to establish the impact of PA on ADHD 
symptoms and its efficacy in alleviating the symptoms and impairments associated with the disorder.  
 
Findings from a study investigating the correlation between cognitions and exercise quantity are 
consistent with the notion that PA may be beneficial for individuals with high levels of ADHD 
symptoms and associated impairments. Exercise quantity was measured each day over a period of 
one week using an accelerometer in 18 boys diagnosed with ADHD. The study found that exercise 
quantity significantly correlated with working memory, inhibition and information processing17. Yet, the 
correlational and non-randomised design prohibits causal interpretations and limits conclusions about 
efficacy. 
 
A study assessing the effects of a 10-week moderate-to-high-intensity exercise programme on fitness, 
cognitive functions and ADHD-related behaviour in 10 children with ADHD compared to a no-
intervention control group consisting of 11 children with ADHD reported significant improvements in 
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muscular capacities, motor skills, level of information processing and parent- and teacher-rated social, 
thought and attention problems following the intervention18. No information is available as to whether 
this study was randomised and blinded.  
 
Three studies investigating the effect of PA in individuals with ADHD have employed a randomised 
prospective design. One of these studies examined the effects of acute exercise on EF19. Thirty 
minutes of moderate-intensity running facilitated selective attention, processing speed and set-shifting 
in 20 children with ADHD who were randomly assigned to the PA group, relative to 20 children with 
ADHD assigned to the control condition of watching a PA-related video19. The second study explored 
the association between chronic PA and attention in 84 children with ADHD. Compared to individuals 
who did not receive an intervention, individuals randomly assigned to a moderate-intensity 10-week 
exercise programme of three sessions per week improved on teacher ratings of attention, motor skills 
and academic and classroom behaviour20. In the third randomised study, teacher-rated 
cooperativeness and EF as indicated by the digit symbol test were significantly improved by 12 bi-
weekly exercise sessions, relative to behavioural educational sessions, in 28 boys with ADHD21. 
While no significant changes were found with regards to hyperactivity scores, inattention scores 
improved in the exercise group. These randomised prospective studies, thus, suggest that PA has 
positive effects on EF and behavioural symptoms associated with ADHD. Yet, none of these studies 
established whether any short-term effects of PA were followed by longer-term benefits. Furthermore, 
none of these studies elaborate on the blinding status of the researchers and informants. 
 
The findings from the studies reviewed above provide some support for the hypothesis that exercise 
has the potential to act as a protective factor for ADHD symptoms and associated impairments. Yet, 
concluding causality from non-randomised, retrospective, and cross-sectional data is problematic. The 
studies looking at case-control differences are also limited by inadequate control conditions and the 
results may, therefore, be confounded by unmeasured genetic and environmental factors that may 
lead to spurious associations. The non-blinded status of the researchers and raters of behaviour may 
further inflate the positive effects of exercise on the various outcome variables due to the non-specific 
effects evoked by a child’ s participation in a treatment programme16. Furthermore, little is known 
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about the developmental influence of PA on ADHD symptoms. The purpose of this study was to 
examine the effect of PA during late adolescence on ADHD symptoms in early adulthood. Both the 
symptoms and functional impairments associated with ADHD often persist from childhood into 
adolescence and adulthood2. While attention problems remain relatively stable, symptoms of 
hyperactivity and impulsivity tend to decline with age22. PA may, thus, be particularly beneficial for the 
age group examined here as PA seems to affect inattention more than hyperactivity/ impulsivity 
symptoms18,20,21. In the light of these findings, the impact of PA on ADHD symptoms is examined 
together and separately for the two sub-components of ADHD, inattention and hyperactivity/ 
impulsivity. Investigating the effect in 232 monozygotic (MZ) twin pairs enables us to control for 
unmeasured genetic and shared environmental confounding factors that may influence the 
relationship between PA and ADHD symptoms, allowing us to draw tentative causal inferences about 
this relationship.  
 
Methods 
Sample 
Data came from the Swedish Twin Study of CHild and Adolescent Development (TCHAD). TCHAD is 
an on-going prospective longitudinal twin study concerning health and behaviour in twins from 
childhood to early adulthood23. The study is a sub-sample of the Swedish Twin Registry, and contains 
about 1,450 twin pairs born in Sweden between May 1985 and December 1986. The twins and their 
parents have been contacted on four different occasions using postal questionnaires. The current 
study used data from waves 3 and 4. The TCHAD sample is representative of the Swedish population 
with regard to educational level and employment status, but not ethnicity23.  In wave 3, the response 
rate was 74 % for parents (n = 1,067), and 82 % for twins (n = 2,369). In wave 4, parents’ response 
rate was 40% (n =1,158) and the twin’s response rate was 59% (n = 1,705)24. The zygosity of 1312 
twins was confirmed by DNA-test during wave 4 when all twins were asked to provide a DNA sample 
with the help of OraGenes DNA (DNA Genotek Inc., Ontario, Canada) self-collection kits. For 1,444 
twins without a DNA sample, zygosity was determined based on an algorithm derived from 
discriminant analyses of twins’ and parents’ responses to validated questionnaires23. In cases of any 
contradictions between the assignments (n=100, 3.4%), the zygosity was set to unknown, and the 
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twins were excluded from the analyses. The present study included 232 monozygotic (MZ) twin pairs 
who had completed self-report measures on PA at age 16-17 and whose parents had completed 
parent-report measures of ADHD symptoms at ages 16-17 and 19-20. The included MZ twins did not 
differ significantly from the individuals lost to follow-up with regards to physical activity levels (t= -0.53, 
df= 767, p= 0.60), ADHD symptoms in adolescence (t= -0.25, df= 839, p= 0.80) and ADHD symptoms 
in early adulthood (t= 0.69, df= 497, p= 0.49). 48.74% of the participants were male. Ethical approval 
was obtained from the Ethics Committee of the Karolinska Institute, Stockholm, Sweden. No informed 
consent was required because, according to Swedish rules, response to the questionnaire constitutes 
consent24.  
 
Measures 
PA is defined as any bodily movement, produced by skeletal muscles, that requires energy 
expenditure. PA is a complex and multidimensional exposure and when assessing its effect, the 
intensity, duration, and frequency with which it is performed must be taken into account25. The twins 
provided self-ratings of their PA by answering three multiple-choice questions enquiring about the 
intensity, frequency, and duration of their leisure-time PA (see Table 1). The intensity indicated by the 
participant was converted into metabolic equivalents of task (MET) using the Compendium of Physical 
Activities26. The average duration per PA session indicated by the participant was converted into 
minutes/ session respectively. PA frequency was converted into PA sessions/ week. Weekly energy 
expenditure (EE) of PA was then calculated using the following formula27:  
Intensity (MET) x Duration (min/ time) x Frequency (times/ week) = weekly EE (MET-min/ week).  
Higher scores indicate greater PA. 
 
At age 16-17, parents completed a binary-coded checklist (0= not true, 1=true) of 14 ADHD symptom 
items based on DSM-IV criteria28. Because of the changes in DSM during the follow-up period of the 
TCHAD study, the full set of all 18 DSM-IV ADHD symptoms were not included29. At age 19-20, 
parents provided ratings of their children’s ADHD symptoms based on the 18 DSM-IV items for 
ADHD28 via a Likert-type scale (0=not true; 1= sometimes true; 2=often true). At both time points, 
parents were asked to check symptoms persisting for at least 6 months. Separate scores for 
	   8 
inattention and hyperactivity-impulsivity as well as a total DSM-IV ADHD symptom score were 
established from these ratings. Higher scores indicate greater symptom severity.  
 
Participants also provided their weight (in kilograms, kg), and height (in meters, m) at baseline. Each 
participant’s body mass index (BMI) was calculated by dividing his  her body weight in kg by his/ her 
height in m squared (kg/ m2). Descriptive statistics for these variables can be found in Table 2. 
 
 
Statistical analysis 
The relationship between PA and ADHD symptoms was investigated using a within-MZ twins fixed-
effect model30 which models within-MZ twin pair differences in ADHD symptoms as a function of 
within-pair differences of weekly EE. Thus, the analysis allows for the effect of PA on ADHD symptom 
levels to be estimated while accounting for unmeasured confounding factors (i.e. all genetic and 
shared environmental factors shared within MZ twin pairs). This is due to the fact that MZ twins share 
100% of their inherited DNA sequence and are expected to share many aspects of their environment 
by virtue of being born at the same time and place and growing up in the same family. As ADHD 
symptoms and BMI31 at baseline were likely to be important confounders for the estimated effect of 
weekly EE on ADHD symptoms at follow-up, we included them in the model. Weekly EE and ADHD 
symptoms were studied as continuous variables. Models were fitted to standardised (Z-) weekly EE 
and ADHD symptom scores. Analyses were performed separately for inattentive, hyperactive/ 
impulsive and total ADHD symptoms. All analyses were conducted in Stata 13.  
 
Results 
The within-MZ twins fixed-effect model revealed that greater weekly EE at age 16-17 significantly 
predicted reduced ADHD symptoms at age 19-20, 𝛽 =  -0.30, p<0.001 (95% CI= -0.46 – -0.15). 
Greater weekly EE at age 16-17 significantly predicted reduced ADHD symptoms at age 19-20 even 
when controlling for ADHD symptoms and BMI at baseline, 𝛽 =  -0.21, p=0.013 (95% CI= -0.38 – -
0.05). Dimension-specific analyses indicated that, even when controlling for baseline BMI and 
hyperactivity/ impulsivity and inattention symptom levels respectively, greater weekly EE at age 16-17 
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was significantly associated with reduced hyperactivity/ impulsivity symptom levels at age 19-20, 𝛽 =  -
0.21, p=0.022 (95% CI= -0.39 –  -0.03), as well as with reduced inattention symptom levels at age 19-
20, 𝛽 =  -0.19, p=0.049 (95% CI= -0.36 – -0.0005). While the effect was slightly larger for hyperactivity/ 
impulsivity symptoms, this difference was not significant, as indicated by the overlapping 95% 
confidence intervals. Because the analyses were carried out using standardised (Z-) scores, the beta 
coefficients presented in this section represent a standardised effect size measure such that one 
standard deviation change in EE leads to beta change in standard deviation in ADHD symptoms. The 
effect size is comparable to Cohen’s d.  
 
Discussion 
In the present study investigating the effect of PA on ADHD symptoms, higher levels of PA, indicated 
by higher weekly energy expenditure, in late adolescence was associated with lower ADHD symptom 
scores in early adulthood, even when adjusting for baseline ADHD symptoms, BMI and unmeasured 
genetic and shared environmental confounding factors. These results are in line with a causal 
hypothesis, indicating that PA may represent a protective factor for ADHD. By using a longitudinal 
design and focusing on weekly energy expenditure rather than a particular kind of exercise, we 
demonstrated that PA might have long-term beneficial effects on ADHD symptoms. These findings, 
therefore, strengthen and extend the limited body of research conducted to date which suggests that 
PA improves symptoms and impairments associated with ADHD16.  
 
While previous research suggested a differential effect of PA on inattention and hyperactivity/ 
impulsivity symptoms18,20,21, we found that PA in late adolescence positively impacted on both 
inattention and hyperactivity/ impulsivity symptom levels in early adulthood. Consequently, PA may 
offer benefits to individuals across development. As ADHD is often chronic, with prominent symptoms 
and impairment spanning from childhood into adolescence and adulthood2, these findings provide 
support for the idea that PA may represent a promising protective factor and novel treatment target for 
ADHD. The implementation of lifestyle changes in the form of more PA incorporated into daily 
routines, promoting an individual’s physical health, behaviour, and neuropsychological functioning, 
may have the potential for flattening the adverse trajectory of the disorder and yielding long-term 
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improvements. However, the effect of PA on ADHD symptoms is small to moderate (-0.21) in this 
population-based sample of twins and further research is needed to firmly establish the positive effect 
of PA and its magnitude in clinical populations. While the pathways via which PA may influence ADHD 
symptoms remain to be elucidated, the up-regulation of brain-derived neurotrophic factor (BDNF) is 
one potential mechanism by which PA could induce its positive effects on ADHD symptoms. However, 
the strength of the association between BDNF and ADHD in humans remain unclear16. 
 
One limitation of this study lies in the use of continuous ADHD symptom ratings in a population-based 
sample rather than a focus on clinically diagnosed cases. Consequently, we cannot be certain that 
these findings will generalise to clinical populations of individuals diagnosed with ADHD and no firm 
conclusions about the clinical utility of PA on ADHD can yet be drawn. Furthermore, the analysis 
yielded a small to moderate effect size (-0.21) with uncertain impact on individuals with high levels of 
ADHD symptoms and impairments. However, the use of a large unselected sample may also be 
regarded as a strength because it decreases the risk of referral and selection biases associated with a 
clinical sample. Another limitation of this study is that we could not control for all factors that were not 
shared between the MZ twins and that may have influenced PA, ADHD symptoms or the association 
between PA and ADHD symptoms. Yet, we were able to adjust for all shared genetic and 
environmental factors by using fixed effects as well as for ADHD symptom levels and BMI at baseline 
(two potentially important unshared confounders of the association). The use of self-report to measure 
PA could be considered a limitation of our study32 because individuals with high levels of ADHD 
symptoms might report less accurately on PA due to difficulties with time estimation, EF and working 
memory. Yet, this issue is likely to be less pronounced in our unselected general population sample. 
Furthermore, our measure of ADHD symptoms has not been formally validated. Although we used 
cross-informant data (i.e., parent-report for ADHD, self-report for PA), relying on a single source of 
informant (e.g. lack of teacher report) to assess ADHD symptoms may be regarded as another 
limitation. However, DSM-based parent-rating scales have been shown to predict interview-based 
diagnoses in childhood and adulthood with adequate sensitivities and specificities33 and our ADHD 
instrument has been used in several epidemiological studies previously and has reproduced several 
well established findings in the ADHD literature29,34–36. Lastly, this study lacked a randomised 
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prospective design. Future randomised control trials will, therefore, have to substantiate the potential 
of PA to act as a protective factor for ADHD. 
 
In line with a causal hypothesis, PA was inversely associated with total ADHD, hyperactivity/ 
impulsivity and inattention symptoms, even after adjusting for unmeasured confounding factors, as 
well as ADHD symptom levels and BMI at baseline, indicating that PA may represent a protective 
factor for ADHD and a novel treatment target. Yet, research into the efficacy of PA as an intervention 
for ADHD is in its infancy. Methodologically robust, blinded, randomised controlled trials employing 
objective measures of PA are needed to investigate the effect of both acute and chronic PA on ADHD. 
In addition, prospective longitudinal studies are needed to establish whether any short-term effects 
are followed by longer-term benefits. In the future the intensity, frequency and duration of PA required 
to yield benefits for individuals with ADHD will need to be established. Whether PA lends itself to early 
intervention and prevention strategies also remains to be elucidated. Studies will need to affirm 
whether and to what extent factors such as age, fitness levels or ADHD symptom severity affect who 
is likely to respond to a PA-based intervention. It remains to be seen what the mechanisms are that 
underlie the positive effect of PA on ADHD symptoms and how far the effect extends beyond the core 
symptoms of ADHD.   
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Table 1.  Physical activity questionnaire enquiring about the intensity, frequency, and duration of the 
participant’s leisure-time physical activity.  
Question 1 How often do you exercise or play sports in your spare 
time? 
Answers 1 1. Never 
2. Less than once a month 
3. 1-2 times a month 
4. About once a week 
5. 2-3 times a week 
6. 4-5 times a week 
7. Almost every day 
Question 2 The intensity of your exercise is comparable to: 
Answers 2 1. Walking 
2. Walking/ jogging 
3. Jogging 
4. Running 
Question 3 On average, how long are your exercise sessions? 
Answers 3 1. Shorter than half an hour 
2. Half an hour to under one hour 
3. One hour to under two hours 
4. Two hour or more 
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Table 2. Descriptive statistics for raw (non-standardised) scores. 
 Mean SD Range 
Weekly EE (MET-min/week) at age 16-17 44.47 30.46 0 – 153 
Total ADHD symptoms at age 16-17 1.12 1.95 0  – 17 
HI symptoms at age 16-17 0.32 0.88 0  –  9 
IA symptoms at age 16-17 0.81 1.45 0  –   8 
BMI at age 16-17 20.6 2.87 11.7 – 33.5 
Total ADHD symptoms at age 19-20 2.50 3.48 0 –  28 
HI symptoms at age 19-20 1.20 1.79 0 –  16 
IA symptoms at age 19-20 1.30 2.18 0  – 18 
SD= standard deviation; EE= energy expenditure; MET-min/ week= metabolic equivalent of task 
minutes per week; ADHD= attention deficit hyperactivity disorder; HI= hyperactive/ impulsive; IA= 
inattentive; BMI= body mass index 
 
